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ABSTRACT 
Objective: The present study describes a simple, accurate, precise, specific and economical UV spectrophotometric method for simultaneous 
estimation of Gliclazide (GLZ) and Sitagliptin phosphate monohydrate (SPM) in bulk and pharmaceutical dosage form.  
Methods: The method was validated in terms of linearity, sensitivity, accuracy, precision, limit of detection and limit of quantification. The solvent 
used was methanol and the absorption maxima for Gliclazide (GLZ) and Sitagliptin phosphate monohydrate (SPM) were found to be 226 nm and 
267 nm respectively.  
Results: The percentage recovery of Gliclazide (GLZ) and Sitagliptin phosphate monohydrate (SPM) were 99.8% and 99.64% respectively. The 
linear response was observed in the range of 7-27 µg/ml and 20-100 µg/ml with a correlation coefficient (r2
Conclusion: The proposed method was successfully applied for the quantitative detection of Gliclazide (GLZ) and Sitagliptin phosphate 
monohydrate (SPM) in Pharmaceutical dosage form. 
) of 0.996 and 0.998 for Gliclazide (GLZ) 
and Sitagliptin phosphate monohydrate (SPM) respectively.  
Keywords: Gliclazide, Sitagliptin phosphate monohydrate, Simultaneous estimation. 
 
INTRODUCTION  
Gliclazide (GLZ) (1-3-azabicyclo [3.3.0] oct-3-yl)–3-p-tolylsulfonyl 
urea or 1-(hexahydrocyclopenta [c] pyrrol-2 (1H)-y1)-3-(p-
tolylsulfonyl) urea is an oral hypoglycemic agent used in the 
treatment of type-II diabetes mellitus (Fig.1) It belongs to the 
sulfonylurea class which act by stimulating β cells of the pancreas to 
release insulin. Its secretion and peripheral insulin resistance, 
increasing the sensitivity of β cells to glucose, decreasing hepatic 
glucose production, and increasing glucose clearance. It also has 
anti-platelet adhesive activity and reduces levels of free radicals, 
thereby preventing vascular complications. It also has been reported 
to reduce plasma cholesterol and triglycerides level after repeated 








Fig. 1: Chemical structure of Gliclazide 
 
Sitagliptin phosphate monohydrate (SPM) chemically, (3R)–3 
amino-1-[3-(trifluoromethyl)-5, 6 dihydro [1,2,4] triazolo [4,3-a] 
pyrazin-7 (8H)-yl]–4-(2,4,5, triflurophenyl) butan–1-one phosphate 
hydrate, is an oral dipeptidyl peptidase–4 (DPP-4) inhibitor for the 
treatment of type-II diabetes mellitus (fig.2) which improves 
glycaemic control by inhibiting DPP-4 inactivation of the incretin 
hormones glucagon like peptide-1 (GLP-1) and glucose–dependent 
insulin tropic polypeptide (GIP). This inhibits glucagon release from 
alpha cells and slows the absorption of nutrients into the blood 
stream and further causes an increase in the amount of insulin 
release from beta cells [7-18]. 
The rationale behind the combination of Gliclazide (GLZ) with DPP-4 
inhibitor Sitagliptin phosphate monohydrate (SPM) has been safe, 
effective and complementary spectrum of anti-diabetic actions. 
when both the combination of drugs reduce HbA1c level and give 












Fig. 2: Chemical structure of sitagliptin phosphate monohydrate 
 
Several methods were reported for the simultaneous estimation of 
Gliclazide (GLZ), Sitagliptin phosphate monohydrate (SPM) alone and 
in combination with other drugs by UV-spectrophotometry [1-18]. 
Literature survey reveals that there is no spectrophotometric 
analytical method for simultaneous estimation of Gliclazide and 
Sitagliptin phosphate monohydrate in bulk and pharmaceutical 
dosage form. Therefore the main novelty of the proposed methods 
was to develop simple, new and economic UV spectrophotometric 
method for the simultaneous estimation of both the drugs in 
combined dosage form.  
MATERIALS AND METHODS 
Reagents and materials 
All chemicals and reagents were used of analytical grade 
Instrumentation 
A Jasco double beam UV-visible spectrophotometer, model: V-630, 
with spectral width in wavelength accuracy of±0.1 nm and a pair of 
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Solubility test for Gliclazide (GLZ) and Sitagliptin phosphate 
monohydrate (SPM) was performed by using various solvents. 
Gliclazide (GLZ) was soluble in methanol and Sitagliptin phosphate 
monohydrate (SPM) was soluble in water. Hence methanol and 
water were selected as solvent for the proposed method. 
Determination of absorption maxima 
Preparation of standard stock solutions 
Gliclazide 10 mg (GLZ) and Sitagliptin phosphate monohydrate 
(SPM) 10 mg were accurately weighed and transferred to two 
separate 10 ml volumetric flask, dissolved in few drops of methanol 
and required amount of water were added to obtain stock solution 
of 1000 µg/ml each. The stock solutions of both the drugs were 
further diluted separately with solvent to obtain 10µg/ml solution 
each and scanned in spectrum mode from 200-400 nm.  
Detection of wavelength 
The drug solutions were scanned between the range of 200-400 nm. 
Gliclazide and Sitagliptin were showed good absorption at 226 nm 
and 267 nm respectively (fig.3, 4) 
 
Fig. 3: λmax of gliclazide 
 
Fig. 4: λmax of sitagliptin phosphate monohydrate 
 
Isobestic point for the combination was found to be 248 nm. The 
overlain spectrum of both the drugs was shown in fig. 5 
Preparation of calibration curve 
The above stock solution, working standard solution of drugs were 
prepared by appropriate dilution and were then scanned in the 
range of 200-400 nm against diluents as blank. A series of dilution 
were prepared for standard solutions Gliclazide (GLZ) and 
Sitagliptin phosphate monohydrate (SPM) 7-27µg/ml and 20-
100µg/ml respectively. The absorbance maxima (λ max) were found 
to be 226 nm and 267 nm for Gliclazide (GLZ) and Sitagliptin 
phosphate monohydrate (SPM). The calibration curve was plotted 
against absorbance Vs concentration. (fig. 6, 7). 
 
Fig. 5: Overlain spectrum of GLZ and SPM 
 
 
Fig. 6: Calibration curve of Gliclazide 
 
 
Fig. 7: Calibration curve of Sitagliptin phosphate monohydrate 
 
Assay of tablet formulation  
Twenty tablets were weighed accurately and freely powdered. 
Tablet powder equivalent of 6 mg of Gliclazide (GLZ) and 10 mg of 
Sitagliptin phosphate monohydrate (SPM) were taken and dissolve 
in 50 ml of methanol and sonicated for 30 minutes. From this 
solution prepare work solutions. The absorbance of the solution was 
measured at respective wavelengths. 
Method validation [19] 
The present UV spectrophtometric methods were validated for 
linearity, sensitivity, precision, accuracy, LOD and LOQ as per ICH 
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guidelines for estimation of Gliclazide (GLZ) and Sitagliptin 
phosphate monohydrate (SPM) in bulk and tablet dosage form. 
 
Table 1: It shows assay of tablet dosage form 
Drug Labelled amount(mg) Amount found %Label claim 
GLZ 60 59.98 99.84 




The repeatability of proposed method was determined by 
performing tablet assay at different time interval on same day 
(intraday) and on three different days (interday) result of intraday 
and interday precision was expressed in % RSD. 
Accuracy 
The accuracy of the method was determined by calculating 
recoveries of Gliclazide (GLZ) and Sitagliptin phosphate 
monohydrate (SPM) by method of standard additions at three 
different levels 80%, 100 %and 120 %. Mean % recovery was 
determined. The percentage recovery values were calculated. 
Linearity 
The linearity of measurement was evaluated by analyzing different 
concentration of the standard solution of Gliclazide (GLZ) and 
Sitagliptin phosphate monohydrate (SPM). The Beer’s Lambert’s 
concentration range was found to be 7-27µg/ml and 20-100 µg/ml 
for Gliclazide (GLZ) and Sitagliptin phosphate monohydrate (SPM) 
respectively. 
Sensitivity 
The sensitivity depends upon the experimental conditions. The 
maximum sensitivity of a method was capable of detection limits. 
The sensitivity of the reaction is important and easily detectable; 
change in intensity must be obtained by small changes in the 
concentration. Sandell’s sensitivity (п) Calculated by using the 
formula 
                     Conc. of drug (µg/100 ml) 
п (µg/cm3
                                                               Absorbance
/AU)=-----------------------------------x 0.001 
 
Table 2: It shows % RSD values of Precision data of GLZ and SPM 
Drugs Parameter Ruggedness 
Repeatability Precision 
 Intraday Interday Analyst 1 Analyst 2 
GLZ 1.130 0.991 1.020 0.97 1.22 
SPM 0.921 0.917 0.886 0.910 0.814 
RSD–Relative Standard Deviation (n=6) 
 
Table 3: It shows Recovery data of GLZ and SPM 
Recovery studies GLZ SPM 
 Amount Present % Label Claim* Amount Present % Label Claim* 
80% 59.98 100.02 99.92 99.54 
100% 60.02 100.04 99.97 99.62 
120% 60.04 100.30 99.64 99.76 
 Mean % Recovery 100.12 Mean % Recovery 99.64 
 
LOD and LOQ 
Limit of detection (LOD) is defined as lowest concentration of 
analyte that can be detected while Limit of Quantification is defined 
as lowest concentrate of analyte that can be quantitated with 
suitable precision and linearity. LOD and LOQ can be calculated from 
the following formula. 
LOQ = 3.3σ/Sand LOQ =10σ/S 
Where σ = is the standard deviation of the regression line  
And s = slope of the calibration curve 
Force degradation study [20] 
Both the drugs Gliclazide (GLZ) and Sitagliptin phosphate 
monohydrate (SPM) were subjected to stress testing as per ICH 
recommended test conditions. The drugs were subjected to acid 
hydrolysis by using 0.1 N hydrochloric acid and alkali hydrolysis 
by using 0.1N sodium hydroxide solution; oxidation by using 
30% v/v solution of hydrogen peroxide, thermal and photolysis 
for ICH Q1B recommended period. The objective of stress study 
was to generate the degradation products under various stress 
conditions. 
 
Table 4: It shows Optical characteristics, regression data of proposed method 
Parameter Result 
GLZ SPM 
λ max (nm) 226 267 
Beer’s law limit (µg/ml) 7-27 20–100 
Sandells’ Sensitivity (µg/cm2 0.0216 /0.001AU) 0.312 
Correlation Coefficient (r2 0.996 ) 0.998 
Slope (m) 0.038 0.0058 
Intercept (i) 0.019 0.0048 
LOD µg/ml 0.31 0.2269 
LOQ µg/ml 0.93 0.685 
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Table 5: It shows Degradation study results of GLZ and SPM 
Degradation study  % Assay 
 GLZ SPM 
Control* 100.06 100.25 
Acidic* 99.92 99.01 
Alkali* 100.04 98.99 
Oxidation* 98.97 98.89 
Thermal* 100.02 99.72 
 * indicates mean of six determinations 
 
DISCUSSION 
A UV-Spectrophotometric method for the simultaneous 
determination of Gliclazide and Sitagliptin phosphate monohydrate 
in bulk and pharmaceutical dosage form was developed and 
validated according to currently accepted ICH guidelines of 
analytical method validation. 
The present work describes the estimation of GLZ and SPM in bulk 
and pharmaceutical dosage form by UV-spectrophotometric method. 
The solvent selected for the study is methanol. There is no analytical 
method available for the selected drugs combination. This method 
merits more economical and better than HPLC. The simultaneous UV 
methods in the present work provides a convenient and accurate 
way for analysis of Gliclazide (GLZ) and Sitagliptin phosphate 
monohydrate (SPM) in its bulk and pharmaceutical dosage form. 
Absorbance maxima of Gliclazide (GLZ) at 226 nm and Sitagliptin 
phosphate monohydrate (SPM) at 267 nm were selected for the 
analysis. The calibration plot for the method was linear over the 
concentration range of 7-27µg/ml and 20-100 µg/ml and 
determination of coefficients (r2) were 0.996 and 0.998 for Gliclazide 
(GLZ) and Sitagliptin phosphate monohydrate (SPM) respectively 
(Table.1). The sensitivity of the method was found to be 
0.021µg/cm3/AUand 0.312μg/cm3
The low Sandell’s sensitivity for the respective method reveals that 
all these methods were highly sensitive. The method was found to be 
precise and as the %RSD values for intraday and interday were 
found to be less than 1% and % recovery 100.12% and 99.64% were 
found to be good at each added concentration, indicating that 
method was accurate for Gliclazide (GLZ) and Sitagliptin phosphate 
monohydrate (SPM) (Table-2,3). The LOD and LOQ were found to be 
0.31µg/ml and 0.93µg/ml for Gliclazide (GLZ) and 0.22µg/ml and 
0.685µg/ml for Sitagliptin phosphate monohydrate (SPM) (Table-4). 
The assay showed that the amount of drug was in good agreement 
with the label claim of formulation as indicated by % assay (99.84%) 
for Gliclazide (GLZ) and (99.97%) for Sitagliptin phosphate 
monohydrate (SPM) (Table-1). There is no interference of the 
degraded products under various stress conditions at the 
recommended period (Table-5). Thus the method was specific for 
simultaneous estimation of Gliclazide (GLZ) and Sitagliptin 
phosphate monohydrate (SPM). 
/AU for Gliclazide (GLZ) and 
Sitagliptin phosphate monohydrate (SPM).  
CONCLUSION 
The developed method has been successfully applied for 
simultaneous determination of Gliclazide (GLZ) and Sitagliptin 
phosphate monohydrate (SPM) bulk and tablet dosage form. Thus it 
may be concluded that it found to rapid, simple, accurate, 
economical, eco friendly and can be adopted for routine analysis of 
drugs in tablet dosage form and as a tool to carryout in process 
quality monitoring and may prove to be great important in 
pharmaceutical analysis. 
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